[Prevention of infections in patients with inflammatory bowel disease during TNF inhibitor treatment].
Treatment of inflammatory bowel disease with anti-tumour necrosis factor (TNF)-alpha biopharmaceuticals is generally well tolerated, but increases the risk of infections due to globally induced suppression of the immune system. National and international guidelines recommend screening and vaccination for selected infectious agents prior to anti-TNF initiation as well as during ongoing anti-TNF therapy. This review focuses on current available recommendations and discusses physicians' and patients' barriers for adherence to guidelines.